ClinicalTrials.gg
Not yet recruitingNCT07889245Updated Oct 22, 2026

A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.

A Phase 2 interventional study of FXR0906 injection and FXR0906 injection in sHTG and HTG With ASCVD (Diagnosed or at Increased Risk), sponsored by Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Primary conditionnone(registry's first term: Disease)No conditionIs this wrong?Disease describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd. (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

Updated Oct 22, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial evaluating the efficacy and safety of FXR0906 in patients with severe hypertriglyceridemia or hypertriglyceridemia with atherosclerotic cardiovascular disease (diagnosed or at increased risk).

Read the detailed description

This phase II study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of FXR0906 injection in sHTG patients or HTG with ASCVD (diagnosed or at increased risk) patients. Eligible enrolled participants will be randomized to receive FXR0906 (dose 1, dose 2 or dose 3) or matched placebo and will be followed up for about 52 weeks.

02

Conditions studied

  • sHTG
  • HTG With ASCVD (Diagnosed or at Increased Risk)

Browse trials for

03

In context

Lead sponsor

Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged between 18 and 75 years (inclusive) at screening;
  2. (BMI) ranging from 18 to 40 kg/m² (inclusive) at screening; body weight >45 kg for female participants and >50 kg for male participants.

3、Fall into at least 1 of the following groups (a or b):

  1. sHTG i) Medical history of fasting TG level ≥500 mg/dL (≥5.65 mmol/L); ii) Mean fasting TG level ≥500 mg/dL (≥5.65 mmol/L), obtained from two separate consecutive visits during the screening period with an interval of at least 7 days and no more than 14 days; iii) Fasting LDL-C ≤130 mg/dL (≤3.37 mmol/L) at screening; or
  2. HTG with ASCVD (diagnosed or at increased risk) i)Medical history of fasting TG ≥200 mg/dL (≥2.26 mmol/L) and \<500 mg/dL (\<5.65 mmol/L), with a confirmed diagnosis of ASCVD (per 2026 AHA/ACC guidelines: including acute coronary syndrome [ACS] (myocardial infarction [MI] and unstable angina), stable angina, coronary or other arterial revascularization, ischemic stroke, [TIA], or history of peripheral arterial disease [PAD]), or increased ASCVD risk (per 2026 AHA/ACC guidelines: participants with a risk ≥5% calculated using the PREVENT-ASCVD risk-calculator); ii) Mean fasting TG level ≥200 mg/dL (2.26 mmol/L) and \<500 mg/dL (5.65 mmol/L), obtained from two separate consecutive visits during the screening period with an interval of at least 7 days and no more than 14 days; iii) Fasting LDL-C ≤130 mg/dL (≤3.37 mmol/L) at screening. 4、 Prior to collection of qualifying TG levels, participants must receive standard-of-care lipid-lowering therapy in accordance with guidelines. For participants with ASCVD (diagnosed or at increased risk), therapy must include cholesterol-lowering agents (e.g., statins); 5. Participants receiving any of the following medications that may affect lipid levels must have the required stable treatment duration prior to screening and maintain stable dosing throughout the study period.

    6、 Willing to follow dietary instructions and maintain a stable low-fat diet throughout the study period.

    7、Participants of must agree to use highly effective methods from screening until at least 9 months after the last dose of IP. Male participants must not donate sperm from screening until at least 9 months after the last dose of IP. Female participants of reproductive potential using hormonal contraception must have stable hormonal contraceptive use for more than one menstrual cycle prior to randomization.

    8. Able to understand and comply with study procedures and willing to provide written form (ICF) prior to performing any study-specific procedures.

Exclusion criteria

Exclusion Criteria:

  1. Current use or use within 365 days prior to screening of any hepatocyte-targeted siRNA or antisense oligonucleotide molecules (including inclisiran);
  2. Known confirmed diagnosis of Familial Chylomicronemia Syndrome (FCS). For participants with suspected FCS without prior diagnosis, genetic testing results must be obtained prior to randomization to rule out FCS;
  3. Uncontrolled hypertension at screening (systolic blood pressure ≥160 mmHg **and/or** diastolic blood pressure ≥100 mmHg);
  4. Occurrence of acute pancreatitis within 12 weeks prior to screening;
  5. Heart failure classified as (NYHA) Class III or IV at screening;
  6. Occurrence of acute coronary syndrome or cerebrovascular events (e.g., myocardial infarction, ischemic stroke) within 24 weeks prior to screening;
  7. Participants who have undergone coronary artery bypass grafting, percutaneous coronary intervention, peripheral vascular revascularization, heart valve replacement or other major surgery within 24 weeks prior to screening, or who plan to undergo major surgery during the study;
  8. Planned bariatric surgery or similar weight-reduction surgery from the time of signing the form through the end of the study;
  9. At screening, diabetic participants with any of the following:

    1. Type 1 diabetes mellitus;
    2. Newly-diagnosed type 2 diabetes mellitus within 12 weeks;
    3. (HbA1c) ≥8.5%;
    4. Hospitalization events related to diabetic ketoacidosis, hyperosmolar hyperglycemic state, other diabetic complications, recurrent infection, or poor glycemic control within 24 weeks prior to screening;
  10. At screening, any of the following laboratory values:

    1. (ALT) or aspartate aminotransferase (AST) >2 × ;
    2. Total >2 × ULN, except in participants with Gilbert's syndrome;
    3. Estimated (eGFR) \<60 mL/min/1.73 m² (calculated using the MDRD formula);
    4. Random urine-protein-to-creatinine ratio >500 mg/g;
    5. count \<100 × 10⁹/L;
    6. abnormalities in (PT), activated partial thromboplastin time (APTT), or international normalized ratio (INR) deemed by the Investigator to render the participant ineligible for the study;
    7. Other clinically significant abnormalities in laboratory safety parameters deemed by the Investigator to render the participant ineligible for the study;
  11. Untreated or inadequately treated hypothyroidism (i.e., thyroid-stimulating hormone [TSH] >2.0 × ULN or free thyroxine [FT4] ≤ lower limit of normal) or hyperthyroidism, as assessed by the Investigator. Participants with well-controlled thyroid disease (stable TSH on stable therapy for at least 4 weeks) are excluded from this criterion;
  12. Medical history of bleeding diathesis or coagulopathy;
  13. Current concomitant nephrotic syndrome;
  14. History of cirrhosis or Class B or C at screening; or history of biliary obstruction;
  15. Positive (HIV) antibody at screening; virus (HBV) infection (positive hepatitis B surface antigen [HBsAg]); active virus (HCV) infection (participants with positive HCV antibody must undergo further HCV RNA testing to rule out active infection); or active syphilis infection;
  16. Active infection requiring systemic antiviral or antibacterial therapy within 2 weeks prior to randomization;
  17. History of within 5 years prior to screening, except for adequately treated basal-cell carcinoma, cutaneous squamous-cell carcinoma, superficial bladder tumor, or carcinoma in situ of the cervix;
  18. Receipt of any of the following therapies:

    1. Systemic or anabolic steroids within 4 weeks prior to randomization or planned use during the study (except for participants with documented history of hypogonadism [low testosterone] on stable-dose testosterone replacement therapy for ≥16 weeks prior to randomization);
    2. Plasma exchange within 4 weeks prior to randomization or planned plasma exchange during the study;
  19. Blood donation of more than 200 mL within 30 days prior to screening;
  20. Unwillingness to limit alcohol consumption during the study (maximum 14 units per week; 1 unit = 80 mL wine, 200 mL beer, or 25 mL of 40-proof spirits);
  21. Intolerance to subcutaneous injection, or skin conditions judged by the Investigator to render subcutaneous injection inappropriate (e.g., surgical wounds, burns). Acceptable injection sites are abdomen, thigh, or upper arm;
  22. Known to the active ingredient or any of the product/placebo;
  23. Participation in another investigational medicinal product trial within 30 days prior to screening (or still within 5 half-lives of the study drug, whichever is longer), or a medical device clinical trial; or plan to participate in another clinical trial during this study; or residual effects deemed present by the Investigator;
  24. Medical conditions that, in the Investigator's judgment, may affect drug absorption, distribution, metabolism, or excretion, or may reduce adherence or increase participant risk; participants who may be unable to complete this study for other reasons, or other conditions rendering the participant unsuitable for study participation as judged by the Investigator.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
192 participants (estimated)

Study arms

  • Experimental
    FXR0906 dose 1

    Dose 1 of FXR0906 injections administrated by subcutaneous injection

    Drug: FXR0906 injection

  • Experimental
    FXR0906 dose 2

    Dose 2 of FXR0906 injections administrated by subcutaneous injection

    Drug: FXR0906 injection

  • Experimental
    FXR0906 dose 3

    Dose 3 of FXR0906 injections administrated by subcutaneous injection

    Drug: FXR0906 injection

  • Placebo comparator
    placebo

    calculated volume to match different dose levels of active treatment by sc injection

    Drug: Placebo

Interventions

  • DrugFXR0906 injection

    2 doses of FXR0906 (dose 1 ) by subcutaneous (sc) injection

  • DrugFXR0906 injection

    2 doses of FXR0906 (dose 2 ) by subcutaneous (sc) injection

  • DrugFXR0906 injection

    2 doses of FXR0906 (dose 3 ) by subcutaneous (sc) injection

  • DrugPlacebo

    The placebo is normal saline (0.9%) and 2 doses of volume matched placebo will be administrated.

06

What researchers measure

Primary outcomes

  1. percent change from baseline at week 24 in fasting triglycerides(TG)

    Time frame: baseline, week 24

Secondary outcomes

  1. percent change from baseline at week 48 in fasting triglycerides(TG)

    Time frame: baseline, week 48

  2. percent change from baseline at week 24 and week 48 in Apolipoprotein (Apo)C-III

    Time frame: baseline, week 24 and week 48

  3. percent change from baseline at week 24 and week 48 in fasting non-high-density lipoprotein cholesterol (non-HDL-C)

    Time frame: baseline, week 24 and week 48

  4. percent change from baseline at week 24 and week 48 in fasting high-density lipoprotein cholesterol (HDL-C)

    Time frame: baseline, week 24 and week 48

  5. percent change from baseline at week 24 and week 48 in fasting Apolipoprotein B (APOB)

    Time frame: baseline, week 24 and week 48

  6. percent change from baseline at week 24 and week 48 in fasting low-density lipoprotein cholesterol (LDL-C)

    Time frame: baseline, week 24 and week 48

  7. number of participants with Treatment-Emergent Adverse Events (TEAEs)T

    Time frame: From first dose of study drug up to Week 60

  8. Changes in Plasma Concentration of FXR0906

    To investigate changes in plasma concentrations of FXR0906 across different dose groups in participants with sHTG or HTG and ASCVD (confirmed or at increased risk)

    Time frame: Day1,Day3,Day169

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Aug 2028, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2026
First posted
Oct 22, 2026
StartEst.
Oct 23, 2026
Primary completionEst.
Aug 24, 2028
CompletionEst.
Dec 24, 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07889245
Responsible party
Sponsor
First posted
Oct 22, 2026
Start date
Oct 23, 2026 (estimated)
Primary completion
Aug 24, 2028 (estimated)
Completion
Dec 24, 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Yida Tang, PhD
Contact
tang_yida@163.com
+86 13901010211
Yu Fu
Contact
lilac_fu@163.com
+86 13671185050

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion